Clinical Research Submission

Last Modified: 4/7/2025, 12:38:51 pm

1. Administration

Name: shanmuka sagar

Department: computer science

Submission Date: 3/7/2025

Review Type: Expedited Review **Study Title:** medical research

Short Title: MR
Protocol: 987897
Version: 8798879

Date: 2025-07-07T18:30:00.000Z

2. Investigators

Type: principal

Name: Shanmuka Sagar

Designation: software engineer

Qualification: B.Tech

Department: computer science

Email: shanmukasagar2019@gmail.com

Contact: 8688345501

Type: guide

Name: shanmuka sagar

Designation: software developer

Qualification: MD, PhD

Department: Clinical Research

Email: shanmukasagar2021@gmail.com

Contact: 9989943631

Type: hod

Name: Bharath

Designation: software engineer

Qualification: B.Tech

Department: computer science

Email: shanmukasagar2023@gmail.com

Contact: 9876543210

3. Investigators Count

PI Count: 12 Co-PI Count: 215 Duration: 213

4. Funding Details

Estimated Budget: 50000

Funding Source: Pharmaceutical Industry sponsored

false

Sponsor Name: fhskfhk sfhsf **Sponsor PAN:** sfhksf sfksf **Sponsor GST:** fskfhskf fh f

Total Grant: ₹ 500 **Budget Items:**

• Per completed patients total sponsor grant: fskfksfhk

• Per completed patients manpower sponsor grant (PI, Co-PI, coordinator,

others): fhskfhksf f

• Per completed patients overhead: fksfhksfhk f

Startup fee: fkhskfh kfhArchival fee: fhshfkf

NIMS Investigations:

Name: fsdffCost: 200Name: fsfCost: 300

Personnel:

• **Designation:** fsff

Fees: fsfsf

• **Designation:** fsfsf

Fees: fsff

Is Outsourced: Yes

Outsourced Investigations:

• Name:

Lab:

NABL:

5. Overview Research

Summary: fsfsf

Study Type: Academic clinical trials

Other Type:

6. Methodology

Sample Size: 250
Participants per Site: 12
Lab Outsourcing: No

Lab Details:

7. Participants

Type: Vulnerable person

Vulnerable Groups:

- Economically and socially disadvantaged
- Unduly influenced due to fear/benefits
- Children (up to 18 years)

Other Participant:

Reimbursement: No

Details:

Additional Safeguards: jgj

Justification: sfsfhskf

8. Benefits

Any Risk: No

Risk Details: Risk Strategy:

Participant Benefits:IndirectSocial Benefits:IndirectScientific Benefits:Indirect

9. Consent

Waiver Consent: Yes

Translated Languages:

Other Reason: gdgdgdggd

10. Payment

Injury Treatment: No

SAE Compensation: No

11. Storage

Docs Control: No **Drugs Control:** No

12. Additional Info

Any Additional: No

Details:

13. Declaration

<% selectedDeclarations.forEach(label => { %>

<%= label %>
 <% }) %>

Principal Investigator

Name: <%= declaration.pi_name %>

Signature: <%= declaration.pi_signature %> **Date:** <%= declaration.pi_date || "N/A" %>

Guide

Name: <%= declaration.guide_name %>

Signature: <%= declaration.guide_signature %> **Date:** <%= declaration.guide_date || "N/A" %>

Head of Department

Name: <%= declaration.hod_name %>

Signature: <%= declaration.hod_signature %> **Date:** <%= declaration.hod_date || "N/A" %>

Co-Investigator 1

Name: <%= declaration.co1_name %>

Signature: <%= declaration.co1_signature %> **Date:** <%= declaration.co1_date || "N/A" %>

Co-Investigator 2

Name: <%= declaration.co2_name %>

Signature: <%= declaration.co2_signature %> **Date:** <%= declaration.co2_date || "N/A" %>

14. Checklist

Cover letter	
Brief CV of all Investigators- Updated, signed and dated	∀iew File
Good Clinical Practice (GCP) training of investigators in last 3 years	∀iew File
EC clearance of other centers	File: null
Agreement between collaborating partners	File: null
MTA between collaborating partners	File: null
Insurance policy / certificate	🕅 View File
Copy of CTA signed with the sponsor	🕅 View File
Provide all significant previous decisions (e.g. those leading to a negative decision or modified protocol) by other ECs / Regulatory authorities for proposed study (whether in same location or elsewhere) and modification(s) to protocol	File: null
Copy of the detailed protocol (clearly identified numbered and dated) and synopsis (summary as far as possible in non-technical language, flowchart, diagrammatic representation of the protocol)	[®] View File
Investigators Brochure (If applicable for drug / biologicals / device trials)	[†] View File

Participant Information Sheet (PIS) and Informed Consent Form (ICF) (English and translated) with version number and dated	⊕ View File
Assent form for minors (12-18 years) (English and Translated)	File: null
Proforma / Questionnaire / Case Report Forms (CRF) / Interview guides / Guides for Focused Group Discussions (FGDs) (English and translated)	⊕ View File
Advertisement / material to recruit participants (fliers, posters, etc.)	File: null
DCGI Approval letter	View File
Others specify	File: null